|
gptkbp:instanceOf
|
gptkb:chemical_compound
antiviral drug
antineoplastic agent
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:ATCCode
|
L01BC06
|
|
gptkbp:brand
|
gptkb:Dacogen
|
|
gptkbp:CASNumber
|
2353-33-5
|
|
gptkbp:category
|
antineoplastic agent
orphan drug
pyrimidine analogue
|
|
gptkbp:chemicalFormula
|
gptkb:C8H12N4O4
|
|
gptkbp:color
|
white
|
|
gptkbp:contraindication
|
pregnancy
severe renal impairment
severe hepatic impairment
|
|
gptkbp:developedBy
|
gptkb:Astex_Pharmaceuticals
|
|
gptkbp:discoveredBy
|
1964
|
|
gptkbp:eliminationHalfLife
|
urine
0.5 hours
|
|
gptkbp:FDAApproved
|
2006
|
|
gptkbp:firstSynthesized
|
gptkb:Marion_Merrell_Dow
|
|
gptkbp:hasSMILES
|
C1=NC(=O)N(C(=N1)N)C2C(C(C(O2)CO)O)O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
decitabine
|
|
gptkbp:IUPACName
|
4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one
|
|
gptkbp:KEGGID
|
D03672
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
DNA methyltransferase inhibitor
|
|
gptkbp:metabolism
|
hydrolysis
|
|
gptkbp:molecularWeight
|
228.21 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
451668
DB01262
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
fever
nausea
fatigue
neutropenia
thrombocytopenia
|
|
gptkbp:solubility
|
soluble in water
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:synonym
|
gptkb:5-aza-2'-deoxycytidine
|
|
gptkbp:target
|
gptkb:DNA_methyltransferase_1
gptkb:DNA_methyltransferase_3A
gptkb:DNA_methyltransferase_3B
|
|
gptkbp:UNII
|
P288Z8EYK6
|
|
gptkbp:usedFor
|
gptkb:acute_myeloid_leukemia
myelodysplastic syndromes
|
|
gptkbp:bfsParent
|
gptkb:SGI-110
gptkb:DNA_methyltransferase
gptkb:Venclexta
|
|
gptkbp:bfsLayer
|
7
|